Inventor · disambiguated record
Glenn D. Crater
Also filed as: CRATER GLENN · CRATER GLENN D · CRATER GLENN DOUGLAS
16 granted patents·10 pending applications·147 citations·filing 2010–2025
93Inventor score
Files withTHERAVANCE BIOPHARMA R&D IP LLC16GLAXO GROUP LTD7BAKER DARRELL1CRATER GLENN1NOVO NORDISK AS1
Top patents by PatentIndex Score
26 records- 0198US10208040B2Fused imidazo-piperidine JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Feb 19, 2019·24 cites·31 claims
- 0297US10548886B2Methods of treatment using a JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 4, 2020·17 cites·18 claims
- 0397US10550118B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Feb 4, 2020·13 cites·10 claims
- 0497US10519153B2Fused imidazo-piperidine JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Dec 31, 2019·16 cites·22 claims
- 0597US10406148B2Methods of treatment using a JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Sep 10, 2019·24 cites·15 claims
- 0697US10392386B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Aug 27, 2019·19 cites·10 claims
- 0795US10251874B2Crystalline forms of a JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2018·Granted Apr 9, 2019·23 cites·23 claims
- 0892US11484531B2Methods for treating chronic obstructive pulmonary diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2019·Granted Nov 1, 2022·5 cites·10 claims
- 0987US2025339413A1Combinations of muscarinic receptor antagonist and a beta-2 adrenoreceptor agonistGLAXO GROUP LTD·Filed 2025·Application pending·0 cites
- 1085US9750726B2Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonistGLAXO GROUP LTD·Filed 2015·Granted Sep 5, 2017·5 cites·17 claims
- 1184US11878977B2JAK inhibitors containing a 4-membered heterocyclic amideTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Jan 23, 2024·0 cites·5 claims
- 1283US12048692B2Methods for treating chronic obstructive pulmonary diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Granted Jul 30, 2024·0 cites·14 claims
- 1382US12285417B2Methods for treating chronic obstructive pulmonary diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2023·Granted Apr 29, 2025·0 cites·16 claims
- 1481US12396986B2Combinations of a muscarinic receptor antagonist and a β-2 adrenoreceptor agonistGLAXO GROUP LTD·Filed 2023·Granted Aug 26, 2025·0 cites·56 claims
- 1581US11667637B2Fused imidazo-piperidine JAK inhibitorsTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Granted Jun 6, 2023·0 cites·19 claims
- 1677US11786517B2Methods of treatment using a JAK inhibitor compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Granted Oct 17, 2023·0 cites·20 claims
- 1777US11090294B2Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonistGLAXO GROUP LTD·Filed 2017·Granted Aug 17, 2021·1 cites·56 claims
- 1876US2023103691A1Methods for treating chronic obstructive pulmonary diseaseTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Application pending·0 cites
- 1973US2022047565A1Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonistGLAXO GROUP LTD·Filed 2021·Application pending·0 cites
- 2068US2020171009A1Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonistGLAXO GROUP LTD·Filed 2020·Application pending·0 cites
- 2158US2025152557A1Methods for treating subjects with abdominal obesity hypertriglyceridemia and/or impaired glucoseNOVO NORDISK AS·Filed 2023·Application pending·0 cites
- 2257US2023021647A1Method of treating a patient infected with a coronavirus and having a baseline level of crp below 150 mg/lTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2022·Application pending·0 cites
- 2352US2021346357A1Method of treating a patient infected with a coronavirus with a dimethyl amino azetidine amide compoundTHERAVANCE BIOPHARMA R&D IP LLC·Filed 2021·Application pending·0 cites
- 2447US2012309725A1Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonistBAKER DARRELL·Filed 2010·Application pending·0 cites
- 2541US2014116434A1Dry Powder Inhaler CompositionsGLAXO GROUP LTD·Filed 2012·Application pending·0 cites
- 2640US2014113888A1Novel Combination of Therapeutic AgentsCRATER GLENN·Filed 2012·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Glenn D. Crater files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →